多发性硬化血液与脑脊液生物标志物的新兴临床应用
综述指出神经丝轻链(NfL)反映复发期急性新发炎症活动所致的轴索损伤,并可提示新发MRI病灶;GFAP在进展型多发性硬化中升高,是独立于复发的进展标志物;CHI3L1与独立于复发活动的进展及顺磁边缘病灶等MRI病灶类型相关。部分标志物尤其NfL有助于监测治疗反应,多变量标志物组合在特定临床场景中提高准确性。体液标志物正快速成为多发性硬化临床病程监测和治疗反应评估的工具。
要点
- NfL升高反映复发期急性炎症活动所致轴索损伤,并可提示新发MRI病灶。
- GFAP在进展型多发性硬化中升高,是独立于复发的进展标志物。
- NfL等标志物可辅助监测治疗反应,多变量组合可提高特定场景准确性。
核心结论
- 在多发性硬化中,体液生物标志物正快速成为临床监测疾病病程和患者治疗反应的工具。
研究设计与样本
- 综述聚焦NfL、GFAP、CHI3L1及其他蛋白检测作为多发性硬化诊断或预后标志物的开发与应用。
主要发现
- NfL浓度升高反映复发期急性新发炎症活动所致的轴索损伤。
- NfL浓度也可反映新发MRI病灶的发生。
- GFAP浓度在进展型多发性硬化患者中升高,是独立于复发的进展新兴标志物。
- CHI3L1是与独立于复发活动的进展及包括顺磁边缘病灶在内的多种MRI病灶类型相关的新兴标志物。
- 部分标志物尤其NfL有助于监测治疗反应,多变量标志物组合在特定临床场景中提供额外准确性。
临床怎么用
- 可将NfL用于辅助监测多发性硬化疾病活动度和治疗反应。
- GFAP和CHI3L1可辅助识别独立于复发的疾病进展。
- 多变量生物标志物组合可在特定临床场景中提高评估准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), chitinase-3-like protein 1 (CHI3L1), and other protein assays are being developed as diagnostic or prognostic biomarkers in multiple sclerosis. An increase in NfL concentrations reflects axonal damage resulting from the acute new inflammatory disease activity that occurs during a relapse. NfL concentrations can also reflect the occurrence of new MRI lesions. GFAP concentrations are increased in people with progressive forms of multiple sclerosis, and GFAP is an emerging biomarker of progression independent of relapses. CHI3L1 is an emerging biomarker associated with progression independent of relapse activity and several MRI lesion types, including paramagnetic rim lesions. Some biomarkers, particularly NfL, can help monitoring treatment response, and combinations of multivariate biomarkers provide additional accuracy in specific clinical scenarios. In multiple sclerosis, fluid-based biomarkers are quickly emerging as instruments for clinical monitoring of disease course and patients' response to treatment.
引用
- Chitnis T, Magliozzi R, Abdelhak A, et al. Blood and CSF biomarkers for multiple sclerosis: emerging clinical applications. Lancet Neurol. 2025. PMID: 41015047. doi:10.1016/S1474-4422(25)00249-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。